
High-grade serous ovarian cancer (HGSOC) accounts for ~70% of ovarian cancers and presents late due to silent progression. Marked by DNA repair defects and genomic instability, it resists early screening. This review explores HGSOC's etiology, pathogenesis, treatments, and tumor microenvironment. It stresses molecular insights for targeted therapies and the need for patient inclusion and diversity in treatment planning to improve outcomes.
Like
Save
Share